Ozmosi | TAK-085 Drug Profile

Product Description

TAK-085 is an oral capsule medicine licensed to Takeda Pharmaceutical Company Ltd. TAK-085 contains omega-3 fatty acid ethyl (mainly, ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoic acid (DHA-E)). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01350999)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: Asia Pacific
Company Founding Year: 1781
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Hyperlipoproteinemias|Hyperlipidemia

Phase 3: Hypertriglyceridemia

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
JapicCTI-163322	JapicCTI-163322	N/A	Completed	Hyperlipidemia	2017-08-30
NCT01350999	TAK-085/OCT-001	P3	Completed	Hypertriglyceridemia	2011-01-01	2024-06-06	Primary Endpoints\|Treatments
NCT01350973	TAK-085/CCT-002	P3	Completed	Hypertriglyceridemia	2010-12-01	2024-06-06
JapicCTI-090936	JapicCTI-090936	P3	Completed	Hypertriglyceridemia	None
JapicCTI-090937	JapicCTI-090937	P3	Completed	Hypertriglyceridemia	None
NCT02824432	Oasis Flow	P4	Completed	Hyperlipidemia\|Hyperlipoproteinemias	2017-08-19	2024-06-06

Recent News Events

Date	Type	Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

TAK-085

Alternative Names: tak-085, tak085, tak 085 Clinical Status: Inactive Latest Update: 2019-05-06 Latest Update Note: Clinical Trial Update